Oppenheimer lowered the firm’s price target on Crispr Therapeutics to $102 from $110 and keeps an Outperform rating on the shares following quarterly results. The firm believes the key focus this year will likely remain on the potential approval and commercial readiness of exacel; as recently disclosed, both the EMA and the MHRA have validated the MAA submissions for exa-cel, and the rolling submissions to the FDA are on track to complete in Q1 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y
- Crispr Therapeutics price target lowered to $82 from $122 at Needham
- Crispr Therapeutics price target lowered to $123 from $153 at Chardan
- Crispr Therapeutics price target lowered to $65 from $78 at Credit Suisse
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
